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Abstract The conformational changes of imatinib (IMT) are
crucial for understanding the ligand–receptor interaction and
its mechanism of action [Agofonov et al. (2014) Nature Struct
Mol Biol 21:848–853]. Therefore, here we investigated the
free energy conformational landscape of the free IMT base,
aiming to describe the three-dimensional structures and ener-
getic stability of its conformers. Forty-five unique conformers,
within an energy window of 4.8 kcal mol−1 were identified by
a conformational search in gas-phase, at the B3LYP/6-31G(d)
theoretical level. Among these, the 20most stable, as well as 4
conformers resulting from optimization of experimental struc-
tures found in the two known polymorphs of IMTand in the c-
Abl complex were further refined using the 6-31+G(d,p) basis
set and the polarizable continuum solvation model. The most
stable conformers in gas-phase and water exhibit a V-shaped
structure. The major difference between the most stable free
conformers and the bioactive conformers consists in the rela-
tive orientation of the pyrimidine–pyridine groups responsible
for hydrogen bonding interactions in the ATP-binding pocket.
The ratio of mole fractions corresponding to the two known (α
and β) polymorphic forms of IMT was estimated from the
calculated thermochemical data, in quantitative agreement
with the existing experimental data related to their solubility.
The electronic absorption spectrum of this compound was
investigated in water and explained based on the theoretical
TD-DFT results, considering the Boltzmann population-
averaged computed data at CAM-B3LYP/6-31+G(d,p) level
of theory for the nine most stable conformers.
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Introduction
Imatinib, which has the IUPAC name 4-[(4-methylpiperazin-
1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-
yl]amino}phenyl)benzamide (IMTor STI-571, see Fig. 1), is a
first generation tyrosine-kinase inhibitor (TKI), usedmainly in
the treatment of chronic myelogenous leukemia and gastroin-
testinal stromal tumors [1–8]. It acts selectively on Abl tyro-
sine kinases [9–11], mast/stem cell growth factor receptor (c-
Kit) and platelet-derived growth factor receptors (PDGF-R)
[12, 13]. Very recently, Halperin et al. [14] demonstrated po-
tential activity of IMT in combination with dacarbazine and
capecitabine for treating endocrine cancers.
In spite of the high expectations related to the efficiency of
this compound, a few drawbacks have been noted recently for
IMT: protonations at nitrogen atoms as a result of pH changes
[15], binding to plasma proteins in a large proportion [16, 17]
and also a differential sensitivity of patients or the develop-
ment of a resistance to the drug for patients under treatment
[11, 13].
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Based on quantum chemical methods, recent works have
addressed the interaction of IMT with Abl TK or calixarenes
aiming at clarifying its mechanism of action [17–21] or at
designing suitable drug carriers for TKIs [15, 22]. For such
purposes, the accurate description of the three-dimensional
(3D) arrangement and molecular properties of thermally ac-
cessible conformational states is crucial [9, 10, 18, 19, 21,
23–25]. Furthermore, analysis of the possible conformers of
a particular drug molecule is mandatory for describing its
spectroscopical properties reliably [26–31]. This is because,
in general, the spectroscopic responses ofmolecules are due to
the collective contributions of their conformers with relative
energies in a narrow range of less than 1 kcal mol−1. Such
behavior is obviously expected also for IMT.
Recently reported X-ray data show that IMT crystallizes in
two polymorphic forms, α and β, with triclinic P-1 symmetry
[17, 32]. From a spectroscopic point of view, IMTwas studied
previously by FT-IR and FT-Raman [33], NMR [34], mass
spectrometry [35–37], HPLC [38–43], capillary electrophore-
sis [44, 45] as well as by UV–vis in different solvents [17, 32,
33, 46–48]. Surprisingly, in spite of the importance of confor-
mational space, to the best of our knowledge, only scarce data
related to the conformers of IMT have been reported in the
literature [19, 23]. Due to its high flexibility, IMT is expected
to adapt easily to different environments. Moreover, as point-
ed out by Agafonov et al. [49], not only the drug, but the
protein itself undergoes structural changes during and after
binding. For this reason, besides the conformational land-
scape, another interest was to compare the 3D structure of
the bioactive conformations found in different IMT-tyrosine
kinases complexes [9, 10, 18, 23] to that of other possible
conformers.
This is why we were interested in the possible conformers
of IMT and their energetic orders. Thus, in the present work
we identified 20 conformers of IMT in water in a relative
Gibbs energy window of 1.69 kcal mol−1. Subsequently, the
most stable nine structures whose relative energies are less
than room temperature energy (0.592 kcal mol−1) were used
to compute the electronic excitation energies, which in turn
were used to explain the experimental observations.
A UV–vis study was conducted to check if the theoretically
identified (most stable) conformers can explain the experi-
mental observations. Moreover, this spectroscopic technique
is (routinely) used to investigate the photosenzing properties
of drugs [50], to identify their possible polymorphic forms
[33] or to study the pharmacokinetic and pharmacodynamic
properties of drugs in patients [51–53]. For these reasons, a
reliable assignment of experimental electronic absorption data
is highly needed, which in this study is given in terms of IMT
monomeric structures.
Methods
Experimental details
Imatinib was purchased from a standard commercial source
(Cayman Chemical, https://www.caymanchem.com) and used
without further purification. UV–vis spectra of IMT in water
were recorded at room temperature using a Jasco V-670 UV–
Vis–NIR spectrophotometer (http://www.jascoinc.com) with
a slit width of 2 nm, in a quartz cuvette of 1-cm path length.
Computational details
The conformational space of IMTwas explored initially with
Tinker software, using the MMFF94 molecular mechanics
force field [54], which was developed based on quantum me-
chanics methods with the specific aim of being used in phar-
maceutical science for predicting molecular geometries, con-
formational energies and energetics of drug–receptor interac-
tions [55–58].
A systematic conformation search was performed using the
MMFF94molecular mechanics force field via Tinker software
(convergence criterion was chosen to the default value of
10−4 kcal mol−1 Å−1). In this way, we identified 4,024 confor-
mations of IMTwithin an energy window of 34 kcal mol−1.
For the next part of the study we used the hybrid B3LYP
exchange-correlation functional [59–62] in conjunction with
Pople’s Bspectroscopic^ 6-31G(d) (BS1) and 6-31+G(d,p)
Fig. 1 a Optimized molecular structures of the most stable conformer of
imatinib (IMT) in water (5) at polarizable continuum model (PCM)-
B3LYP/6-31+G(d,p) level of theory, with the atom numbering scheme.
b Superimposed optimized structures of the most stable conformer of
IMT in water (5) at three levels of theory, as indicated in the bottom left
corner
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(BS2) basis sets [63]. The first 45 most stable conformers,
whose relative free energies are less than 3.5 kcal mol−1 were
subsequently re-optimized in gas-phase at B3LYP/BS1 level
of theory. Besides these, we also optimized the geometries of
IMT conformers found in the two known polymorphic forms
and in c-Abl kinase complexes, using their solid state
structures as starting geometries. A total number of 49 con-
formers were optimized, whose relative energy spans a free
energy interval from 0 to 4.80 kcal mol−1. Finally, the gas-
phase structures were re-optimized in water at B3LYP/BS1
and B3LYP/BS2 levels of theory, using the PCM continuum
solvation model [64]. Table 1 and Fig. 2 present the first nine
Table 1 Polarizable continuum model (PCM)-B3LYP/6-31G+(d,p) calculated dihedral angles (degrees) characterizing the nine most stable imatinib
(IMT) conformers in water
Conformer Φ1 Φ2 Φ3 Φ4 Φ5 Φ6 Φ7 θ,α, β
a
T-A-C-C-C-C+T- (5) −166.8 −129.0 −29.0 −3.6 1.2 0.7 −155.8 132.2
21.6
50.9
T-G+C+C+C-C+C+ (16) −167.6 52.8 −29.3 −6.7 −0.1 −0.4 24.7 95.7
20.4
76.9
T-G+C+C+C-C+C- (13) −167.5 54.2 −28.7 −6.4 −0.2 −0.8 −24.6 96.5
−21.3
45.4
T-G+C-C-C+C+T+ (6) −167.6 54.5 −28.4 −6.3 3.0 0.3 156.7 95.3
−16.1
47.0
T-G+C-C-C-C-T- (3) −167.5 53.9 −28.8 −6.4 1.6 0.2 −156.4 95.3
21.4
45.4
G-A+C+C+C+C-T- (7) −68.6 129.8 29.0 3.4 −0.8 −0.5 −156.1 130.8
18.8
50.0
T-G+C-C-C-T+T+ (10) −166.3 52.0 −29.4 −6.6 −11.1 177.9 154.4 30.1
−35.7
42.2
T-G+C-C+C+T-T- (18) −167.1 54.2 −27.5 −4.5 5.8 −177.0 −153.1 34.8
31.9
49.5
T-G+C-C-C+T-T- (14) −167.1 54.2 −27.5 −4.5 5.8 −177.0 −153.1 34.8
26.1
49.6
α-form −167.7 48.8 −29.2 169.9 −6.1 −0.8 −156.2 149.0
13.2
38.8
β-form −167.5 52.2 27.8 180.0 −111.0 −6.8 156.4 123.0
38.0
71.0
A-c-Abl −166.6 46.0 27.3 −175.4 112.8 5.3 156.6 120.7
77.6
83.6
B-c-Abl −168.0 53.4 27.6 −176.3 112.3 5.4 −23.7 116.8
78.2
66.2
a As defined in [19]
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most stable conformers thus obtained, whose relative energies
are less than the room temperature energy (0.592 kcal mol−1).
For comparison purposes we also included the two optimized
and experimental structures of the conformers found in the c-
Abl kinase complex and in the α and β polymorphs.
Frequency calculations confirmed that all the optimized
geometries correspond to minima on the potential energy sur-
face (PES). The optimization of IMT geometry and calcula-
tions of vibrational frequencies were performed with the
Gaussian09 software package [65].
Boltzmann weighting factors for each conformer were de-
rived at room temperature (T=298K) by using the relative free
energies (ΔG). The latter values were obtained from frequency
calculations including thermal corrections to energies [66].
Absorption spectra of IMTwere calculated using the time-
dependent DFT (TD-DFT) methodology [67] implemented in
the Gaussian09 package, which describes the excited states in
terms of all possible single excitations from occupied to vir-
tual orbital. For this purpose we used the long-range corrected
CAM-B3LYP functional [68] coupled to the 6-31+G(d,p) ba-
sis set, and the excitation energies were calculated on the IMT-
optimized structures at B3LYP/BS2 level of theory.
The simulated UV–vis spectrum of IMT in the 180–
400 nm range has been obtained by summation of contribu-
tions from transitions to the first 80 singlet excited electronic
states. The UV spectral line-shapes were convoluted with
Gaussian functions with FWHM of 0.96 eV, as derived from
experimental spectra.
Figures representing the structures of IMT were created
using the Mercury 3.3 [69] and Molegro Molecular Viewer
[70] program packages.
Results and discussion
Conformation landscape
Imatinib conformers can be generated by varying the torsion
angle around seven rotatable bonds (see Fig. 1): N30–C29,
C29–C26, C23–C21, N20–C16, C14–N13, N13–C11 and
C7–C3. Table 1 summarizes the dihedral angles Φ1–Φ7 that
characterize the 20 most stable conformers whose structures
are shown in Fig. 2. Their names, relative Gibbs energies and
populations are summarized in Table 2. Besides the 20 most
Fig. 2 PCM-B3LYP/6-31+
G(d,p) optimized structures of the
nine most stable IMT conformers
in water, together with α and β
crystal forms [32], as well as the
A- and B-forms found in the
kinase complex of c-Abl [71]
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stable conformers, Fig. 2 includes also the optimized confor-
mations of IMT obtained by using as starting geometries the
structures found in α and β polymorphs [32] and two struc-
tures (A and B) found in the c-Abl-imatinib complex [71].
To name the conformers we employed the usual terminology
in polymer stereochemistry [72, 73], using the four letters C, G,
A and T, each followed by a + or − sign, depending on the value
of the angle to which the letter is assigned (see Scheme S1).
Namely, the particular value of each of the dihedral angles
Φ1–Φ7 that define the conformation of IMT (see Fig. 1) con-
tributes with a doublet formed from one letter and a (+ or −)
sign to the whole name of the conformer. Thus, with respect to a
given bond and its associated dihedral angle, a conformer is: C−
or C+ (cis) type for an angle between−30° and 0° or 0° and 30°,
respectively, T− or T+ (trans) type for an angle between −180°
and −150° or 150° and 180°, respectively, G− or G+ (gauche)
type for an angle between −90° and −30° or 30° and 90°,
respectively, or A− or A+ (anticlinal) type for an angle between
−150° and −90° or 90° and 150°, respectively.
It is important to note here that, for IMT’s conformers, there
are two kind of structural transformations that do not affect
their energies: the first is related to the rotation of the benzene
ring along the C23–C26 axis, while keeping all the other di-
hedrals unchanged. Such transformations involve changes in
the dihedrals Φ2 → N30–C29–C26–C27 and Φ3 → C28–
C23–C21–N20.
Another transformation that changes the structure, but not
the energy, is a mirror symmetry, related to transformation of
dihedral angle Φ1→ C35–N30–C29–C26 and the change of
sign of the other six dihedral angles. To avoid counting the
symmetry-related conformations, only those conformers that
have the first dihedral angle negative and the third dihedral
angle between −30 and 30° are considered in Table 2.
The conformational analysis shows that for each dihedral
angle there are four different conformers. Because of the two
symmetries mentioned above, the number of different con-
formers is 47/(2×2) = 4,096, the theoretical maximum value
being just a bit larger than 4,024, the value obtained with
Tinker software and the MMFF94 force field.
The most visible difference between the C and T type con-
formers can be observed between those containing these let-
ters in the sixth doublet, i.e., differing in the rotation around
the N13–C14 bond. The conformers with the sixth doublet as
C− and C+ have a V-shape, [19], while the conformers having
Table 2 Relative free energies and Boltzmann populations of the 20 most stable conformers of imatinib in gas-phase [B3LYP/6-31G(d) level of
theory] and in water [PCM-B3LYP/6-31G(d) and PCM-B3LYP/6-31+G(d,p) levels of theory] at room temperature
Conformer Gas-phase B3LYP/6-31G(d) Water PCM-B3LYP/6-31G(d) Water PCM-B3LYP/6-31+G(d,p)
ΔGa (kcal mol−1) Population (%) ΔGb (kcal mol−1) Population (%) ΔGc (kcal mol−1) Population (%)
G-A+C-C-C+C-T- (1) 0.00 16.24 0.31 6.15 1.06 1.85
G-A+C-C-C+C+T- (2) 0.40 8.38 0.35 5.75 1.07 1.83
T-G+C-C-C-C-T- (3) 0.40 8.37 0.26 6.64 0.27 7.07
G-A+C-C-C+C-T+ (4) 0.44 7.82 0.14 8.12 0.66 3.67
T-A-C-C-C-C+T- (5) 0.48 7.28 0.00 10.33 0.00 11.13
T-G+C-C-C+C+T+ (6) 0.69 5.16 0.35 5.74 0.26 7.22
G-A+C+C+C+C-T- (7) 0.71 4.95 0.51 4.38 0.34 6.29
G-G-C-C-C+C+T- (8) 0.72 4.84 0.85 2.49 0.65 3.72
T-G+C+C+C-C+T- (9) 0.74 4.72 0.83 2.58 0.94 2.28
T-G+C-C-C-T+T+ (10) 0.97 3.22 0.16 7.86 0.41 5.57
G-A+C-C-C+C-C- (11) 0.97 3.20 0.29 6.31 0.63 3.87
T-G+C+C+C+T-T- (12) 0.97 3.19 1.18 1.45 0.78 3.00
T-G+C+C+C-C+C- (13) 1.02 2.97 0.42 5.14 0.03 10.59
T-G+C-C-C+T-T- (14) 1.04 2.87 0.47 4.73 0.49 4.84
T-G+C-T+C-T+T- (15) 1.04 2.84 1.12 1.59 1.69 0.64
T-G+C+C+C-C+C+ (16) 1.05 2.83 0.15 8.07 0.03 10.63
G-A+C-C-C+C-C+ (17) 1.05 2.81 0.43 5.05 1.09 1.76
T-G+C-C+C+T-T- (18) 1.05 2.79 0.48 4.66 0.49 4.86
T-A-C+C-C-T-C+ (19) 1.06 2.77 1.13 1.56 0.98 2.13
G-A+C-C-C+T-T- (20) 1.06 2.76 1.20 1.38 0.72 3.30
a Relative to conformer (1)
b Relative to conformer (5)
c Relative to conformer (5)
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the sixth doublet T− and T+ are U-shaped (see Fig. 2 and
Tables 1 and S1). It is important to note that only conformer
(15) (see Table S2) has an S-like shape, closest to that of the
α and β polymorphs and to the structures found in IMT-c-Abl
complexes.
Special attention must be paid to the piperazine fragment of
IMT, which is a radical of N,N′-dimethyl-piperazine. In the
chair form of N,N′-dimethyl-piperazine, which, according to
our calculations, is more stable than the skewed boat by
8.23 kcal mol−1 [relative Gibbs energy calculated at B3LYP/
6-31G(d) level of theory], the two N–CH3 bonds can remain
equatorial or axial, leading to three different conformations,
eq–eq, eq–ax and ax–ax, with relative Gibbs energy of 0.00,
6.47 and 7.69 kcal mol−1, respectively. The most stable con-
former in gas-phase (1) has the piperazine fragment in the
chair form with eq–eq conformation. According to data pre-
sented in Table 1 and Fig. 2, the chair conformation is pre-
served for all IMT conformers considered within a relative
Gibbs energy of 0.49 kcal mol−1.
As shown in Table 2, the first nine most stable conformers
in water are dominant, constituting more than 68 % of the
Boltzmann population. The most stable conformer in gas-
phase is (1), while conformer (5) is the most stabilized in
water; the main differences between the structures of the two
conformers consist in the relative orientation of the piperazine
group relative to the rest of the molecule (see Table S1). Such
a difference is expected considering that this group represents
the hydrophobic moiety of IMT [19]. The conformers (16),
(13), (6), (3), (10), (18) and (24) are U-shaped molecules (see
Fig. 2) with a value of θ angle below 97°. The α dihedral
angle between the pyridine and methylbenzene rings has
values between 50°and 90° in type II inhibitor-protein com-
plexes, but for the first nine most stable free IMT conformers
in Table 1, α values oscillate between −35° and 32° (see
Table 1). The hydrogen interactions of the pyridine and
pyrimidine groups of IMT with the aminoacids of the ATP
pocket rotate the plane of these groups relative to the plane
of the methylbenzene ring.
The β dihedral angle between piperazine and the
methylbenzene group is distributed largely between 0° and
90° in protein–imatinib complexes and the same happens for
the free conformers, whose β values are between 42° and 77°
(see Table 1).
Table 3 lists the experimental dihedral angles of IMT as
found in the c-Abl kinase complex [71], but also the α and
β polymorphic forms [32] (see their structures in Fig. 2). The
dihedral angleΦ5 for IMT in tyrosine kinase complex is 97.5°,
giving rise to a value of 92.6° for theα angle, characteristic for
type II inhibitors. There is also a large value of 77.7 and
−113.3° of dihedral angle Φ5 in the α and β crystal form,
respectively. In contrast, according to the data presented in
Table 1, this dihedral in the free conformers in water with
relative Gibbs energies less than 0.592 kcal mol−1 is limited
to small values between −11.1° and −5.8°. The hydrogen
bonding interactions of IMT in the tyrosine kinase complex
and in the mesylate crystal constrain the molecule to a less
stable conformer with larger relative Gibbs energy than the
isolated counterpart in water, by 1.60 – 1.77 kcal mol−1.
Notably, only conformer (15) has an S-like shape, resembling
the conformation found in both solid state polymorphs [32]
and the c-Abl-IMT complex [71]. Moreover, from Fig. 2 it is
evident that the major difference between the structures of the
free V-shape conformers and the bioactive conformer bound
to c-Abl kinase consists of the relative orientation of the
pyrimidine–pyridine groups. It is this moiety through which
the IMT ligand binds to the ATP pocket of TK.
To conclude the discussion about the structural features of
IMT conformers, we would like to note that the BS1 basis set
was demonstrated as a good compromise for obtaining opti-
mized geometries, relative energies and even excitation
Table 3 Experimental and PCM-B3LYP/6-31+G(d,p)-calculated
dihedral angles (degrees) and relative free energy characterizing the
IMT α and β crystal forms [22] and the A-form and B-form in the
tyrosine kinase complex [59] and their optimized conformers in water.
Exp. Experimental data, Opt. Optimized; A, B The two forms found in c-
Abl kinase complexes with IMT [59]; α, β the two structures determined
in the α and β polymorphs of imatinib [22]
ΔGa Φ1 Φ2 Φ3 Φ4 Φ/5 Φ6 Φ7
Exp. A [59] n.a.b −179.0 49.4 15.7 −176.6 97.5 −0.5 170.3
Opt.-Awater 1.77 −166.6 46.0 27.3 −175.4 112.8 5.3 156.6
Exp. B [59] n.a. −179.8 49.4 24.6 −179.8 97.5 −0.5 −12.1
Opt.-B water 1.60 −168.0 53.4 27.6 −176.3 112.3 5.4 −23.7
Exp. α [22] n.a. −165.7 43.5 −25.8 −164.6 77.9 −26.9 36.6
Opt. α water 1.19 −167.7 48.8 −29.2 −168.7 −6.1 −0.8 24.4
Exp. β [22] n.a. −168.3 23.7 35.3 −129.2 −113.3 −3.9 −13.2
Opt. β water 1.47 −167.5 52.2 27.8 −0.6 −111.0 −6.8 −24.1
a Relative to conformer (5)
b Not available
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energies, at least for small or medium-sized molecules
[74–80]. Such properties are somehow Bsystem dependent^,
i.e., in some cases the experimentally derived properties are
accurately reproduced even with a small basis set like 6-
31G(d). For spatially extended molecules like IMT, the rela-
tive conformational energies could be affected significantly by
using more flexible basis sets.
However, as shown in Fig. 1b, slight differences were
noted between the geometries of the conformer (5) obtained
by using the two basis sets. Actually, the only significant
differences were observed for the relative orientations of the
CH2–benzene and pyridine–pyrimidine groups. Thus, the Φ1
and Φ7 dihedrals change from −140.4° and −161.2°, to
−129.0° and −155.8°, respectively. The effect of the xc func-
tional on geometries was tested for conformer (5) only. We
observed that the influence was marginal, the largest differ-
ence between the B3LYP and CAM-B3LYP functionals (of
1.82°) being observed for the Φ2 angle that describes the
orientation of the methylene CH2 group relative to the
benzene moiety.
Quantitatively, for this conformer, the average root mean
square deviation (rmsd) between the backbone atoms in case
of the B3LYP functional coupled to the two basis sets was
0.192 Å, while the rmsd between B3LYP and CAM-B3LYP
functionals, both coupled to the BS2 basis set, was 0.035 Å.
On the other hand, the basis set drastically affects the rela-
tive stability of the conformers. Thus, as seen in Table S2, the
energetic order of the conformers with relative free energy
within the room temperature energy is (5), (4), (16), (10),
(3), (11), (1), (2), (6), (13), (17), (14), (18), (7) for BS1, but
it changed to (5), (16), (13), (6), (3), (7), (10), (18), (14) in case
of the BS2 basis set. The total relative population of these two
sets of conformers also changed from 85.61 to 68.21 %.
Regarding the two polymorphic forms of IMT, it is possible
to estimate the difference in fusion enthalpies between two
polymorphic forms as the difference between the enthalpies
of conformers in gas-phase [81, 82]. Thus, for an ideal solu-
tion, the mole fraction x of solute at saturation is a function of
fusion enthalpy ΔH, molar heat capacity ΔCp, the melting
temperature Tm and the temperature T of the solution [81]:
x ¼ exp − ΔH=Rð Þ⋅ 1=T−1=Tmð Þ þ ΔCp=R
 
⋅ Tm−Tð Þ=Tþ ln T=Tmð Þð Þ
 
For IMT, the difference in fusion enthalpy is estimated as
Hβ–Hα = 2.45 kJ mol
−1 and the difference in molar heat ca-
pacityΔCp is approximated by the difference in fusion entropy
(ΔSβ–ΔSα = −3.67 J K−1 mol−1) for transition from crystal
form to supercooled liquid form (that is calculated for the
two polymorphic states α and β as ΔS = Sgas–Swater). For
estimating the xα/xβ ratio we used the equation:
xα=xβ ¼ exp Hβ−Hα
 
=R⋅ 1=T−1=Tmmð Þ− ΔSβ−ΔSα
 
=R⋅ Tm−Tð Þ=Tþ ln T=Tmmð Þð Þ
 
where Tmm = 494.5 K is the average value of the experimental melting temperatures of the two polymorphs [32]. Using the above
equation and estimations we obtained at room temperature (T = 298 K) a value of 2.26 for the ratio of mole fractions, in excellent
agreement with experimental finding that α-form polymorph is 2.5 times more soluble than the β-form.
In addition, considering the difference in experimental fu-
sion enthalpies between β and α forms of 3.18 kJ mol−1 [32]
our calculations predict that 2.45 kJ mol−1 is due to confor-
mational difference and 0.73 kJ mol−1 is due to the difference
of the Van der Waals interactions in crystal.
UV–vis spectra
Figure 3 illustrates the evolution of the UV–vis spectrum of
IMT in water as a function of concentration within the 10−5–
10−4 M range. While a clear red-shift of the peak around 195–
203 nm is observed by increasing the concentration, the other
two absorbance peaks at 237 and 257 nm do not change their
positions. By increasing the concentration, a slight
bathochromic shift and hypochromism is observed for the
peak around 200 nm. These effects are most probably a result
of the interaction between the solute and solvent molecules
[83–85].
The absorption peak at 257 nm was observed in other sol-
vents between 258 and 268 nm in water at a different pH [17],
at 277 nm inmethanol [8, 33], at 273 nm in ethanol [17] and at
275 nm in acetonitrile [50].
Recently reported data demonstrated that for molecules
with large spatial extent, the calculated electronic transition
energies can be improved significantly by using the long-
range corrected CAM-B3LYP functional [86–91]. For this
reason, we decided to calculate the UV–vis spectrum of IMT
at CAM-B3LYP/BS2//B3LYP/BS2 level of theory.
For concentrations lower than 10−4 M it is assumed that the
monomers contribute predominantly to the absorption spec-
trum in solution. Due to the small relative Gibbs energies of
the conformers it is expected that the experimental spectrum
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measured at room temperature represents a thermal average
over the UV–vis spectra of different conformers. The relative
Gibbs energies (ΔG) and populations given in Table 2 suggest
that the predominant contribution to UV–vis spectra of ima-
tinib in water comes from the nine most stable imatinib mono-
mers (5), (16), (13), (6), (3), (7), (10), (18) and (14) whose
relative energies are within 0.49 kcal mol−1 and together con-
stitute more than 68 % of the total population.
The simulated spectrum shown in Fig. 3 was obtained as the
sum of absorbance contributions of the nine most stable con-
formers in water, weighted by their Boltzmann population at
room temperature. Calculated transitions energies, oscillator
strengths and transition contributions are collected in Table 4.
As shown in Fig. 3, the positions and intensities of the exper-
imental bands are very well reproduced by calculations, in-
cluding the molar absorption coefficient (see Fig. S1). We
would like to mention that the use of the common B3LYP
functional for excitation energies calculations leads to much
larger discrepancies between experiment and theory. Thus, in
that case, the largest calculated lambda is 281 nm, that is, a
difference of 24 nm from its experimental counterpart, in a
range commonly encountered in the literature [91–94] for this
property.
According to quantum chemical calculations, each of the
nine most stable conformers of IMT give mainly four calcu-
lated absorption bands: around 190 nm, due mainly to
HOMO-6 → LUMO + 4 transition; at 254 nm, due to
HOMO-2→ LUMO + 1 transition; at 265 nm, due to HOMO
→ LUMO + 1 transition and 270 nm due to HOMO →
LUMO + 1 and HOMO→ LUMO + 2 transitions.
The shapes of the molecular orbitals involved in the above-
mentioned transitions of (5) in water are shown in Fig. 4. The
Table 4 Time-dependent density functional theory (TD-DFT) CAM-
B3LYP/6-31G+(d,p)//B3LYP/6-31+G(d,p) calculated electronic
transitions of the ninemost stable conformers of IMTat room temperature
in water
Conformer λ(nm) fa Transitions Contributions % b
(5) 269.6 0.69 H→L+1 38.41
H→L+2 18.67
265.1 0.49 H→L+2 28.78
H→L+1 27.37
H→L+3 17.53
254.1 0.78 H-2→L+1 20.97
189.6 0.64 H-6→L+4 14.00
(16) 269.7 0.65 H→L+1 37.64
H→L+2 16.14
H→L+3 15.81
265.2 0.48 H→L+1 28.11
H→L+2 24.82
H→L+3 20.99
253.6 0.78 H-2→L+1 20.03
H-3→L+1 13.31
189.6 0.41 H-6→L+4 28.64
(13) 269.9 0.65 H→L+1 39.60
H→L+2 15.03
H→L+3 14.85
265.3 0.49 H→L+1 26.35
H→L+2 25.93
H→L+3 21.86
253.7 0.78 H-2→L+1 22.29
188.8 0.46 H-6→L+4 15.26
(6) 269.8 0.65 H→L+1 40.14
H→L+2 17.68
H→L+7 13.18
265.2 0.51 H→L+2 30.25
H→L+1 25.84
H→L+3 17.90
253.9 0.79 H-2→L+1 22.95
189.6 0.77 H-6→L+4 26.70
(3) 269.7 0.65 H→L+1 39.44
H→L+2 18.14
H→L+7 13.17
265.2 0.51 H→L+2 29.70
H→L+1 26.51
H→L+3 17.81
253.8 0.79 H-2→L+1 21.86
189.5 0.64 H-6→L+4 25.21
(7) 269.5 0.69 H→L+1 38.30
H→L+2 18.75
265.1 0.49 H→L+2 28.86
H→L+1 27.47
H→L+3 17.32
254.1 0.78 H-2→L+1 22.23
Fig. 3 Concentration dependence of the absorption spectra of IMT in
water at room temperature. The simulated spectrum was calculated as
Boltzmann population averaged spectra at room temperature of the nine
most stable conformers in water. The stick spectrum corresponds to
conformer (5)
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highest energy observed transition (HOMO-6→ LUMO + 4)
at 190 nm is due mainly to a redistribution of electronic
charge onto the phenyl moiety. The electronic transition
HOMO-2 → LUMO + 1 at 254 nm is a result of charge
transfer from methylbenzene and piperazine rings to the phe-
nyl group, concomitant with a redistribution of charge within
the methylbenzene ring. This HOMO-2 → LUMO + 1
electronic transition is most probably responsible for the ab-
sorption peak at 234–243 nmobserved in water at different pH
[17], at 238 nm in methanol [8, 33], at 228 nm in ethanol [17]
and at 230 nm in acetonitrile [50].
As seen in Fig. 4, the HOMO orbital is delocalized onto the
methylbenzene, pyrimidine and amide group. The lowest en-
ergy electronic transitions HOMO → LUMO + 1 and
HOMO-LUMO + 2 simulated in water at 258 nm and ob-
served experimentally at 257 nm are due to charge transfer
from the methylbenzene and pyrimidine groups to the phenyl
ring. This is in agreement with Nardi et al. [50], who observed
for compound 1 resulted from a combination of the
methylbenzene and pyrimidine rings, an absorption peak in
acetonitrile at 270 nm.
It is worth mentioning here that the use of a continuum
solvation model for calculating the electronic absorption spec-
trum of IMT could be questionable. However, very recent
studies show that, for similarly large systems, the calculated
excitation energies are influenced primarily by the geometry
of the chromophore itself, with marginal contributions from
specific solute–solvent interactions [79, 95], and that the im-
plicit solvation model is sufficient to predict solvent effects
with acceptable accuracy [89].
Further improvement of the agreement between experi-
ment and theory could be achieved in three ways: (1) by cal-
culating the vibronic structure of the absorption spectrum
[96]; (2) by using the explicit solvation model, possibly within
the QM/MM approach [97]; (3) reoptimizing the geometry of
IMT using the CAM-B3LYP xc functional.
The possibility that the peak observed at 237 nm is part of
the vibronic structure is ruled out since the difference between
this peak and that seen at 257 nm corresponds to a vibrational
mode with an energy of about 3,284 cm−1, which is not pos-
sible for IMT.
Because of the large size of the investigated molecule, the
second possibility presumes very time consuming tasks, with-
out any expected qualitative improvement [79, 95]. The last
option was, however, taken into account by using the same
CAM-B3LYP/6-31+ G(d,p) level of theory for both geometry
optimization and TD-DFT runs. The calculated excitation en-
ergies of the first three most intense transitions in the case of
the most stable conformer in water (5) came closer to the
experimental data by about 3 nm, while the higher energy
transitions are affected by less than 1 nm. This is at the ex-
pense of a slight worsening observed in the reproduction of
the relative intensities of the absorption bands.
Conclusions
Combining molecular mechanics and DFT quantum chemis-
try methods we were able to characterize 20 conformers of
Table 4 (continued)
Conformer λ(nm) fa Transitions Contributions % b
189.5 0.72 H-6→L+4 20.16
(10) 269.4 0.37 H→L+1 33.32
H→L+2 15.69
H→L+6 13.26
265.2 0.58 H→L+1 31.73
H→L+2 26.56
H→L+3 19.92
190.3 0.33 H-6→L+4 13.88
(18) 269.9 0.38 H→L+1 38.65
H→L+2 13.89
H→L+6 13.75
265.3 0.60 H→L+1 27.57
H→L+2 26.68
H→L+3 24.28
253.9 0.30 H-2→L+1 30.23
189.5 0.26 H-6→L+4 27.38
(14) 269.9 0.38 H→L+1 38.65
H→L+2 13.89
H→L+6 13.75
265.3 0.60 H→L+1 27.57
H→L+2 26.68
H→L+3 24.28
253.9 0.31 H-2→L+1 30.23
189.5 0.25 H-6→L+4 27.84
a Only transitions with f >0.25 are included
bOnly contributions >10 % are included
Fig. 4 CAM-B3LYP/6-31+G(d,p) calculated density plots of the
molecular orbitals involved in the main electronic transitions of IMT
conformer (5) in water
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IMT, all of them being confirmed as minima on the PES. The
relative Gibbs energies of the nine most stable IMTmonomers
in water were within 0.49 kcal mol−1 and together constitute
more than 68 % of the total population. Conformational data
could be useful for further studies aimed at describing reliably
the binding site of IMT or similar drugs within Bcr-Abl or
other tyrosine kinases.
In water solution, IMT presents three UV–vis absorbance
peaks in the range 195–203 nm, 237 and 257 nm. A reliable
assignment of the electronic transitions of IMT is provided
based on the Boltzmann populations-averaged spectra of its
conformers in water. The lowest energy absorption peak
observed at 257 nm has its simulated counterpart at 258 nm,
and the transition is a result of charge transfer from the
methylbenzene and pyrimidine groups to the phenyl moiety.
While the 6-31G(d) basis set seems to be an optimum
choice for geometry optimizations of IMT and, presumably,
for similar drugs, the 6-31+G(d,p) is required for relative en-
ergies and excitation energy calculations. Only by using the
CAM-B3LYP long range corrected functional was it possible
to reproduce quantitatively the lowest energy electronic ab-
sorption peak.
Based on the calculated thermochemical data, a value of
2.26 was estimated for the ratio of mole fractions xα/xβ cor-
responding to the two known polymorphs of IMT, in excellent
agreement with previously published experimental findings.
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